Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome
Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome
复制标题
单体核型是高危骨髓增生异常综合征患者生存的独立预测因子
DOI：
10.1002/ajh.23801
复制
发表时间：
2014-10-01
影响因子：
12.8
通讯作者：
Xiao, Zhijian
中科院分区：
文献类型：
--
作者：
Xing, Ruixian;Li, Chengwen;Xiao, Zhijian
单体核型（MK）与急性髓细胞白血病患者的生存率低相关，尽管这是否也适用于骨髓增生异常综合征（MDS）患者仍存在争议。一些研究报告了MK和较差生存率之间的相关性，而另一些研究则声称这种相关性是由于MK和复杂核型（CK）之间的混杂效应引起的。为了解决这个问题，我们分析了610例成人MDS患者的临床资料和核型。在60例患者中确定了MK，其中55例（92%）也符合CK标准。相反，在85例患者中发现CK，其中55例（65%）也有MK。为了确定MK对生存率的影响，对464例接受非强化治疗的MDS患者进行了单独分析。单因素分析显示，MK患者的生存期比无MK患者差（中位数8个月[95%CI，3-12个月] vs 83个月[63-103个月]; P
A monosomal karyotype (MK) correlates with poor survival in patients with acute myeloid leukemia, although whether this is also the case in patients with myelodysplastic syndrome (MDS) remains controversial. Some studies report a correlation between a MK and a worse survival, whereas others claim that this correlation arises because of a confounding effect between a MK and a complex karyotype (CK). To address this question, we analyzed the clinical data and karyotypes of 610 adults with MDS. A MK was identified in 60 patients, of whom 55 (92%) also fulfilled the criteria for a CK. Conversely, a CK was found in 85 patients, of whom 55 (65%) also had a MK. To determine the impact of a MK on survival, 464 patients who received nonintensive therapies for MDS were analyzed separately. Patients with a MK demonstrated worse survival than those without a MK in univariate analyses (median, 8 months [95% CI, 3-12 months] versus 83 months [63-103 months]; P